Andrés Marcelo Córdova López

Andrés Marcelo Córdova López

Auto-generated profile, based on publicly available information

Andrés Marcelo Córdova López

Independiente

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Educational Regent Multidisciplinary Journal
Verified
Journal Article
Open access
PDF file
CTCésar Eduardo Ceja Tovar
César Eduardo Ceja Tovar
JCJose Ruben Romero Castellares
Jose Ruben Romero Castellares
MGMario Alfonso Blanco Gomez
Mario Alfonso Blanco Gomez
JAJosé Enrique González Araujo
José Enrique González Araujo
ELErick Trejo López
Erick Trejo López
CCCristian Alonso Duarte Carreño
Cristian Alonso Duarte Carreño
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, yet conventional predictive models often fail to capture the complex interplay of genetic and physiological risk factors in diverse populations. This study evaluated a hybrid predictive model integrating polygenic risk scores (PRS), artificial intelligence (AI) applied to electrocardiography (ECG), and traditional clinical variables to enhance cardiovascular risk prediction across Latin American cohorts from Mexico, Colombia, and Ecuador. A total of 6,450 participants aged 30 to 75 years were analyzed. PRS were derived from genome-wide association data, and ECGs were processed using deep convolutional neural networks. Model performance was assessed using AUROC, F1-score, and calibration metrics, with interpretability achieved through SHAP (Shapley Additive Explanations) analysis. The hybrid model demonstrated superior predictive accuracy (AUROC 0.91; F1-score 0.87; calibration slope 0.97) compared with the clinical (0.72), PRS (0.78), and AI-ECG (0.86) models. The most influential predictors were PRS, systolic blood pressure, age, and AI-derived electrical age. Subgroup analyses revealed consistent performance across ancestries (Mestizo 0.91; Amerindian 0.89; European 0.93; Afro-descendant 0.87) and countries, confirming the model’s generalizability and fairness. These findings demonstrate that integrating genetic and AI-based physiological data significantly improves cardiovascular risk assessment, enabling early, equitable, and personalized prevention. The proposed hybrid framework provides a scalable foundation for implementing AI-driven genomic precision medicine in multi-ancestry populations, marking an essential step toward reducing cardiovascular disparities in Latin America.

1 July 2025 in Imperium Académico Multidisciplinary Journal
Verified
Journal Article
Open access
PDF file
MGMartín Gomez-Lujan
Martín Gomez-Lujan
MAMelina Lucia Pineda Aguilar
Melina Lucia Pineda Aguilar
JAJosé Enrique González Araujo
José Enrique González Araujo
DLDaniela María Fernández Lugo
Daniela María Fernández Lugo
IVIvan Alfonso Velasco
Ivan Alfonso Velasco
ALAndrés Marcelo Córdova López
Andrés Marcelo Córdova López
Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD) worldwide, and incretin-based therapies have emerged as potential tools for organ protection beyond glucose control. This multicenter prospective study compared renal, metabolic, and cardiovascular outcomes in adults with type 2 diabetes mellitus (T2DM) treated with GLP-1 receptor agonists (GLP-1 RAs) or dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) across Mexico, Colombia, and Ecuador between 2023 and 2024. A total of 512 patients (298 GLP-1 RA, 214 GIP/GLP-1 RA) were followed for 12 months. Dual GIP/GLP-1 therapy showed a significantly smaller annual eGFR decline (−0.6 vs. −1.5 mL/min/1.73 m²; p=0.001) and greater albuminuria reduction (−27.4% vs. −19.0%; p=0.02), with more participants achieving ≥30% UACR reduction (43.9% vs. 34.2%; p=0.04). Improvements in HbA1c (−1.8% vs. −1.2%), body weight (−9.1 vs. −6.4 kg), and systolic blood pressure (−8.4 vs. −6.8 mmHg) were also greater with dual therapy (all p<0.05). Inflammatory and oxidative stress markers decreased more significantly in the GIP/GLP-1 group (IL-6 −34.8%, CRP −42%, MDA −1.4 μmol/L; all p<0.02). Major renal events (CKD stage ≥4 or ≥40% eGFR decline) and cardiovascular outcomes (heart failure hospitalization, myocardial infarction, cardiovascular death) were less frequent with dual agonists, translating to a 28% relative risk reduction in composite cardiorenal events (HR 0.72; 95% CI 0.54–0.96; p=0.02). These findings demonstrate that dual GIP/GLP-1 receptor agonists provide superior renal preservation, metabolic optimization, and cardiorenal protection compared with GLP-1 RAs alone, supporting their integration into early DKD management.